Key Highlights

  • Pre-market trading on November 3, 2026 lifted shares 8.37% to USD 0.769.
  • Third quarter 2026 results are due November 5, 2026 at 8:30 a.m. ET.
  • Per a June 24, 2026 filing, the FDA agreed on a pivotal Phase 3 study of zervimesine in dementia with Lewy bodies.
  • Cash stood at about USD 34.8 million on June 30, 2026, which should last into the fourth quarter of 2027.
  • On October 13, 2026 the company announced a composition of matter Patent running zervimesine protection to 2045.

Pre-Market Action Before the Bell (up USD 0.0594, 8.37%)

Cognition Therapeutics, Inc. (NASDAQ:CGTX) climbed 8.37% to USD 0.769 in pre-market dealings on November 3, 2026, compared with the Monday, November 2, 2026 close. The sole company release located in the recent window is a November 2, 2026 notice that a third quarter call will take place on November 5, 2026.

That notice offers no fresh data, so the rise seems to reflect some positioning ahead of results alongside normal volatility. Shares priced under USD 1.00 qualify as a penny stock, a category where thin trading, abrupt price swings and dilution risk are routine.

The Upcoming Earnings Release

In a press release dated November 2, 2026, management said it will host a call and webcast at 8:30 a.m. ET on November 5, 2026 covering the quarter ended September 30, 2026, along with a Business update.

Comparing against the second quarter helps frame expectations: the company posted a net loss of USD 3.9 million, or USD 0.04 per share, versus USD 6.7 million a year earlier. Research and Development spending dropped to USD 5.1 million from USD 11.5 million, largely because trial activity slowed.

Pipeline Overview

Cognition Therapeutics is a clinical-stage biopharmaceutical developer. Its flagship candidate, zervimesine (CT1812), is an investigational once-daily oral medicine that showed encouraging Phase 2 results in dementia with Lewy bodies and mild to moderate Alzheimer's disease, while the company also pursues geographic atrophy and Parkinson's.

A June 24, 2026 filing states the FDA concurred that psychosis in dementia with Lewy bodies may be an approvable outcome. The planned Phase 3 would randomize participants to 100 mg of zervimesine or placebo over nine months, using the Neuropsychiatric Inventory as its primary endpoint, with a start targeted for mid-2027.

Cash Position and Funding Pressures

The company reported roughly USD 34.8 million in cash, cash equivalents and restricted cash equivalents at June 30, 2026, lower than USD 37.0 million at December 31, 2025, and indicated that this would support operations into the fourth quarter of 2027. Because a Phase 3 effort will probably require additional capital, financing and share dilution stand out as principal risks.

Second-quarter grant income came in at USD 3.5 million, versus USD 7.1 million previously, while unspent obligated funds from the National Institute on Aging totaled USD 21.6 million.

Points to Track Next

The November 5, 2026 release should reveal the cash balance, the rate of spending and any change to the Phase 3 schedule or trial funding.